197.85 -6.60 (-3.23%)
- 1D
- 5D
- 1M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
195.05
Today’s High
206.35
52 Week Low
201.55
52 Week High
386.99
197.80 -6.70 (-3.28%)
- 1D
- 5D
- 1M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
195
Today’s High
206.7
52 Week Low
201.5
52 Week High
387.45
Key Metrics
- Market Cap (In Cr) 2946.03
- Beta 1.91
- Div. Yield (%) 0
- P/B 0.77
- TTM P/E -
- Sector P/E 28.26
- D/E 0.62
- Open Price 205.65
- Prev Close 204.45
Analysis
Price Analysis
-
1 Week-8.36%
-
3 Months-14.18%
-
6 Month-5.04%
-
YTD-8.32%
-
1 Year-43.97%
Risk Meter
- 38% Low risk
- 38% Moderate risk
- 38% Balanced Risk
- 38% High risk
- 38% Extreme risk
Recos
0 Analysts
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Wockhardt News
Anand Rathi sees 10% upside in this pharma stock in short term. Should you buy?
2 min read . 25 Aug 2022
Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2022
- Total Revenue
- 3230
- Selling/ General/ Admin Expenses Total
- 1353
- Depreciation/ Amortization
- 247
- Other Operating Expenses Total
- 225
- Total Operating Expense
- 3362
- Operating Income
- -132
- Net Income Before Taxes
- -411
- Net Income
- -244
- Diluted Normalized EPS
- -10.37
- Period
- 2022
- Total Assets
- 8243
- Total Liabilities
- 4394
- Total Equity
- 3849
- Tangible Book Valueper Share Common Eq
- 132.24
- Period
- 2022
- Cashfrom Operating Activities
- 413
- Cashfrom Investing Activities
- -201
- Cashfrom Financing Activities
- -71
- Net Changein Cash
- 138
- Period
- 2021
- Total Revenue
- 2708.3
- Selling/ General/ Admin Expenses Total
- 1251.53
- Depreciation/ Amortization
- 246.02
- Other Operating Expenses Total
- 248.68
- Total Operating Expense
- 3157.37
- Operating Income
- -449.07
- Net Income Before Taxes
- -568.34
- Net Income
- 686.06
- Diluted Normalized EPS
- -22.32
- Period
- 2021
- Total Assets
- 7772.69
- Total Liabilities
- 4395.93
- Total Equity
- 3376.76
- Tangible Book Valueper Share Common Eq
- 130.56
- Period
- 2021
- Cashfrom Operating Activities
- -287.32
- Cashfrom Investing Activities
- 1470.1
- Cashfrom Financing Activities
- -1170.82
- Net Changein Cash
- 12.91
- Period
- 2020
- Total Revenue
- 2843.99
- Selling/ General/ Admin Expenses Total
- 1152.7
- Depreciation/ Amortization
- 224.14
- Other Operating Expenses Total
- 265.41
- Total Operating Expense
- 2970.37
- Operating Income
- -126.38
- Net Income Before Taxes
- -342.04
- Net Income
- -69.22
- Diluted Normalized EPS
- -13.64
- Period
- 2020
- Total Assets
- 8178.91
- Total Liabilities
- 5507.24
- Total Equity
- 2671.67
- Tangible Book Valueper Share Common Eq
- 74.94
- Period
- 2020
- Cashfrom Operating Activities
- 648.96
- Cashfrom Investing Activities
- -155.53
- Cashfrom Financing Activities
- -679.58
- Net Changein Cash
- -178
- Period
- 2019
- Total Revenue
- 3565.84
- Selling/ General/ Admin Expenses Total
- 1462.74
- Depreciation/ Amortization
- 163.95
- Other Operating Expenses Total
- 340.44
- Total Operating Expense
- 3742.91
- Operating Income
- -177.07
- Net Income Before Taxes
- -446.55
- Net Income
- -194.53
- Diluted Normalized EPS
- -24.13
- Period
- 2019
- Total Assets
- 7844.31
- Total Liabilities
- 5169.51
- Total Equity
- 2674.8
- Tangible Book Valueper Share Common Eq
- 99.57
- Period
- 2019
- Cashfrom Operating Activities
- 183.32
- Cashfrom Investing Activities
- 94.57
- Cashfrom Financing Activities
- -776.44
- Net Changein Cash
- -499.9
- Period
- 2018
- Total Revenue
- 3936.9
- Selling/ General/ Admin Expenses Total
- 1705.17
- Depreciation/ Amortization
- 149.53
- Other Operating Expenses Total
- 360.54
- Total Operating Expense
- 4500.05
- Operating Income
- -563.15
- Net Income Before Taxes
- -641.15
- Net Income
- -608.3
- Diluted Normalized EPS
- -29.64
- Period
- 2018
- Total Assets
- 8162.04
- Total Liabilities
- 5309.89
- Total Equity
- 2852.15
- Tangible Book Valueper Share Common Eq
- 126.54
- Period
- 2018
- Cashfrom Operating Activities
- 68.44
- Cashfrom Investing Activities
- 630.24
- Cashfrom Financing Activities
- -769.47
- Net Changein Cash
- -66.4
- Period
- 2017
- Total Revenue
- 4014.61
- Selling/ General/ Admin Expenses Total
- 1792.39
- Depreciation/ Amortization
- 148.93
- Other Operating Expenses Total
- 318.69
- Total Operating Expense
- 4137.32
- Operating Income
- -122.71
- Net Income Before Taxes
- -247.15
- Net Income
- -195.72
- Diluted Normalized EPS
- -16.32
- Period
- 2017
- Total Assets
- 9021.68
- Total Liabilities
- 5684.97
- Total Equity
- 3336.71
- Tangible Book Valueper Share Common Eq
- 186.25
- Period
- 2017
- Cashfrom Operating Activities
- -269.47
- Cashfrom Investing Activities
- -686.27
- Cashfrom Financing Activities
- 1254.49
- Net Changein Cash
- 301.03
- Period
- 2022-09-30
- Total Revenue
- 679
- Selling/ General/ Admin Expenses Total
- 163
- Depreciation/ Amortization
- 65
- Other Operating Expenses Total
- 215
- Total Operating Expense
- 896
- Operating Income
- -217
- Net Income Before Taxes
- -230
- Net Income
- -189
- Diluted Normalized EPS
- -4.33
- Period
- 2022-09-30
- Total Assets
- 7834
- Total Liabilities
- 4340
- Total Equity
- 3494
- Tangible Book Valueper Share Common Eq
- 101.55
- Period
- 2022-09-30
- Cashfrom Operating Activities
- 61
- Cashfrom Investing Activities
- -103
- Cashfrom Financing Activities
- -141
- Net Changein Cash
- -183
- Period
- 2022-06-30
- Total Revenue
- 595
- Selling/ General/ Admin Expenses Total
- 180
- Depreciation/ Amortization
- 64
- Other Operating Expenses Total
- 204
- Total Operating Expense
- 675
- Operating Income
- -80
- Net Income Before Taxes
- -96
- Net Income
- -67
- Diluted Normalized EPS
- -4.64
- Period
- 2022-06-30
- Period
- 2022-06-30
- Period
- 2022-03-31
- Total Revenue
- 654.56
- Selling/ General/ Admin Expenses Total
- 180.79
- Depreciation/ Amortization
- 59.47
- Other Operating Expenses Total
- 231.68
- Total Operating Expense
- 929.67
- Operating Income
- -275.11
- Net Income Before Taxes
- -347.2
- Net Income
- -258.04
- Diluted Normalized EPS
- -11.36
- Period
- 2022-03-31
- Total Assets
- 8243
- Total Liabilities
- 4394
- Total Equity
- 3849
- Tangible Book Valueper Share Common Eq
- 132.24
- Period
- 2022-03-31
- Cashfrom Operating Activities
- 413
- Cashfrom Investing Activities
- -201
- Cashfrom Financing Activities
- -71
- Net Changein Cash
- 138
- Period
- 2021-12-31
- Total Revenue
- 853.89
- Selling/ General/ Admin Expenses Total
- 197.8
- Depreciation/ Amortization
- 61.98
- Other Operating Expenses Total
- 209.84
- Total Operating Expense
- 802.05
- Operating Income
- 51.84
- Net Income Before Taxes
- -28.56
- Net Income
- -6.78
- Diluted Normalized EPS
- -0.56
- Period
- 2021-12-31
- Period
- 2021-12-31
- Period
- 2021-09-30
- Total Revenue
- 862
- Selling/ General/ Admin Expenses Total
- 178.15
- Depreciation/ Amortization
- 61.21
- Other Operating Expenses Total
- 238.4
- Total Operating Expense
- 813.93
- Operating Income
- 48.07
- Net Income Before Taxes
- -29.24
- Net Income
- 33.53
- Diluted Normalized EPS
- 2.77
- Period
- 2021-09-30
- Total Assets
- 8009.18
- Total Liabilities
- 4617.2
- Total Equity
- 3391.98
- Tangible Book Valueper Share Common Eq
- 127.34
- Period
- 2021-09-30
- Cashfrom Operating Activities
- 248.57
- Cashfrom Investing Activities
- -145.12
- Cashfrom Financing Activities
- -85.06
- Net Changein Cash
- 17.95
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Technical
Moving Average
SMA
- 5 Day214.35
- 10 Day219.28
- 20 Day223.74
- 50 Day228.07
- 100 Day237.65
- 300 Day242.27
Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Indoco Remedies
- 338.45
- -10.25
- -2.94
- 427.82
- 307.95
- 3212.36
- Advanced Enzyme Technologies
- 272.25
- -2.35
- -0.86
- 355.15
- 257
- 3067.28
- Wockhardt
- 197.85
- -6.6
- -3.23
- 386.99
- 201.55
- 2946.03
- Strides Pharma Science
- 308.1
- -14.25
- -4.42
- 413.5
- 263.45
- 2914.26
- Marksans Pharma
- 62.9
- -1.05
- -1.64
- 69.6
- 38.7
- 2897.98
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Indoco Remedies
- 20.56
- 3.55
- 8.71
- 5.26
- Advanced Enzyme Technologies
- 25.84
- 2.79
- 15.57
- 26.97
- Wockhardt
- -
- 0.77
- -10.45
- -10.27
- Strides Pharma Science
- -
- 1.23
- -0.14
- -0.17
- Marksans Pharma
- 14.18
- 2.18
- 19.29
- 11.2
Shareholding
- Category
- Percentage
- No. of shares
- Public Shareholding
- 39.64%
- 57,104,077
- Others
- 25%
- 36,008,458
- Rekha Rakesh Jhunjhunwala
- 2.08%
- 3,000,005
- Others
- 3.17%
- 4,577,467
- Others
- 3.29%
- 4,742,847
- Others
- 2.86%
- 4,118,784
- HUF
- 1.26%
- 1,819,665
- LLP
- 0.4%
- 581,498
- Clearing Members
- 0.1%
- 147,554
- Director or Director's Relatives
- 0.01%
- 11,000
- Unclaimed or Suspense or Escrow Account
- 0.01%
- 10,200
- Trusts
- 0%
- 1,950
- Others
- 1.05%
- 1,516,183
- Others
- 0.18%
- 266,412
- Others
- 0.16%
- 226,844
- Others
- 0.04%
- 55,405
- Foreign Bank
- 0.01%
- 10,200
- Foreign Institutional Investors
- 0%
- 1,200
- Others
- 0%
- 5,549
- Others
- 0%
- 1,475
- Others
- 0%
- 751
- Others
- 0%
- 630
- Promoter & Promoter Group Shareholding
- 60.36%
- 86,956,076
- Themisto Trustee Company Private Limited
- 49.41%
- 71,174,744
- Callirhoe Trustee Company Private Limited
- 3.54%
- 5,096,751
- Pasithee Trustee Company Private Limited
- 3.52%
- 5,070,000
- Ananke Trustee Company Private Limited
- 3.08%
- 4,434,530
- Habil F Khorakiwala
- 0.41%
- 597,286
- Murtaza Habil Khorakiwala
- 0.2%
- 294,060
- Huzaifa Habil Khorakiwala
- 0.19%
- 280,800
- Nafisa Habil Khorakiwala
- 0%
- 5,565
- Miqdad H Khorakiwala
- 0%
- 2,340
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 04-Nov-22
- Quarterly Results
- 12-Aug-22
- Quarterly Results
- 30-May-22
- Audited Results
- 03-Mar-22
- Rights issue
- 27-Jan-22
- Quarterly Results
- 06-Jan-22
- Rights issue of Equity Shares
- 08-Nov-21
- Quarterly Results
- 22-Jul-21
- Quarterly Results
- 27-May-21
- Audited Results & Others
- 21-May-21
- Others
- Meeting Date
- Announced on
- Purpose
- 02-Aug-21
- 08-Jul-21
- AGM
No recent dividend announcements.
No recent bonus announcements.
No recent splits available.
- Announced on
- Record Date
- Ex-Rights Date
- Ratio
- FV
- Premium
- Description
- 06-Jan-22
- 09-Mar-22
- 08-Mar-22
- 3:10
- 5
- 220
- Rights issue of equity shares of Rs. 5/- each in the ratio of 3:10 @ premium of Rs. 220/-.
Company Profile
ABOUT Wockhardt
- Industry Biotechnology & Drugs
- ISIN INE049B01025
- BSE Code 532300
- NSE Code WOCKPHARMA
Wockhardt Limited is a pharmaceutical and biotechnology company. The Company's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines. It manufactures a range of dosage forms, including sterile injectables and lyophilized products. The Company offers products in therapeutic areas of dermatology, cosmeceuticals, oncology, medical nutrition, osteoarthritis, pain management, nephrology, cough therapy and diabetology. The Company’s products across India includes Citawok, Citawok Forte, Citawok Plus, CONSEGNA 30/70 U-200 CART, CONSEGNA R U-200 CART, DARBOTIN PFS, DECDAN, DECDAN B, DECDAN B Injection, DECDAN LITE CREAM, Emrok, Emrok O, Erliso, FOSCHEK-S, Gabawok NT, GLARITUS CART, GLARITUS DISPO, Glimaday, INOGLA, Livatira, GLARITUS CART and VAL 450. The Company has approximately three research centers globally and a chain of six super-specialty hospitals across Maharashtra and Gujarat.
MANAGEMENT
- Habil Fakhruddin Khorakiwala Executive Chairman of the Board
- Pramod Gupta Chief Financial Officer
- Debashis Dey Chief Compliance Officer, Company Secretary
- Murtaza Habil Khorakiwala Managing Director, Executive Director
- Huzaifa Habil Khorakiwala Executive Director
Company Summary
WOCKHARDT SUMMARY
Wockhardt is trading 3.23% lower at Rs 197.85 as compared to its last closing price. Wockhardt has been trading in the price range of 206.35 & 195.05. Wockhardt has given -8.32% in this year & -8.36% in the last 5 days.
The company posted a net profit of -189 Crores in its last quarter.
Listed peers of Wockhardt include Indoco Remedies (-2.94%), Advanced Enzyme Technologies (-0.86%), Wockhardt (-3.23%) etc.
Wockhardt has a 60.36% promoter holding & 39.64% public holding.
FAQs about Wockhardt
Wockhardt is trading at 197.85 as on 27 Jan, 2023 3:55:02 PM. This is -3.23% lower as compared to its previous closing price of 204.45
The market capitalization of Wockhardt is 2946.03 Cr as on 27 Jan, 2023 3:55:02 PM.
The 52 wk high for Wockhardt is 386.99 whereas the 52 wk low is 201.55
Wockhardt can be analyzed on the following key metrics -
- TTM P/E: -
- Sector P/E: 28.26
- Dividend Yield: 0%
- D/E ratio: -
Wockhardt reported a net profit of -244 Cr in 2022.
